Drug news
Phase II success of SAR236553/REGN727 for Cholesterol Lowering
Regeneron/Sanofi announced data from two
Phase II trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously
administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology�s (ACC) 61st Annual Scientific Meeting in Chicago. The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or �bad� cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.